文档介绍：阿托伐他汀对进展性脑梗死进展时间及神经功能的影响
作者:李森范爱琴冯书现景宏源
【摘要】目的探讨阿托伐他汀对进展性脑梗死进展时间及神经功能缺损程度的影响。方法选取200501~200812住院的进展性脑梗死86例,随机分为治疗组和对照组各43例,对照组:NS 250 ml+奥扎格雷针80 mg,1次/d 静滴,NS 250ml+复方丹参针20ml,1次/d静滴,NS 250ml(或5%GS 250ml)+ 1次/d静滴,低分子肝素钙针5000U,1次/12h,皮下注射,连用5d。治疗组在对照组基础上加用阿托伐他汀片20mg,入院后立即口服,继而1次/d口服,连用4周。观察入院时、进展停止时、发病4周时神经功能缺损程度和发病至症状达高峰时间。结果 2组在发病至症状达峰时间、发病4周时NIHSS评分方面差异均有统计学意义。结论进展性脑梗死应用阿托伐他汀安全,可改善预后。
【关键词】进展性脑梗死;阿托伐他汀;神经功能缺损程度;预后
【Abstract】 Objective To investigate the effect of atorvastatin on progressive cerebral infarction ment time and lack of nerve function. Methods From January 2005 to December 2008, 86 cases were randomly divided into treat ment group of 43 cases and control group of 43 cases. Control group: NS 250 ml+ augerneanapin 80 mg, one time intravenous drip each day, NS 250 ml + danshen 20 ml, one time intravenous drip each day, NS 250 ml(or 5% GS 250 ml )+ citicoline , one time intravenous drip each day, LMWH 5000U, 12 h each time, subcutaneous (or h
ypodermic) injection,continu onsly using 5 days. Treatment group should plus use atorvastatin 20 mg on the basis of control group while in hospital and continuously using for 4 weeks. The influences of degree of nervous functional defects and symptom up to peak time were The two groups had the significant difference on grade of NIHSS while onset, up to peak Atorvastatin on